STOCK TITAN
  1. Home
  2. News
  3. AXNX

Axonics Inc - AXNX STOCK NEWS

Welcome to our dedicated news page for Axonics (Ticker: AXNX), a resource for investors and traders seeking the latest updates and insights on Axonics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axonics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axonics's position in the market.

News
Axonics to Present at the J.P. Morgan Healthcare Conference
Rhea-AI Summary
Axonics, Inc. (Nasdaq: AXNX) to Present at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
conferences
-
News
BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors
Rhea-AI Summary
BiVACOR, Inc. (Nasdaq: BVCR) announced the appointment of Raymond W. Cohen as chairman of its board of directors. The company also received FDA approval for a first-in-human clinical feasibility study of its total artificial heart (TAH) system. The study will evaluate the safety and feasibility of the TAH as a bridge to heart transplant in the treatment of subjects with biventricular heart failure. Approximately 100,000 patients suffering from severe heart failure could benefit from BiVACOR's unique TAH, according to the U.S. National Institutes of Health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
management
-
News
Axonics to Participate in November Investor Conferences
Rhea-AI Summary
Axonics, Inc. (Nasdaq: AXNX) will be participating in two investor conferences in November. The company will present at the Wolfe Research Healthcare Conference on November 14 at 12:30 p.m. Eastern Time and at the Piper Sandler Healthcare Conference on November 29 at 10:30 a.m. Eastern Time. Interested parties can access a live webcast and replay of each presentation on the Axonics investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
conferences
News
Axonics Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Axonics, Inc. reported quarterly revenue of $93.1 million, a 32% YoY increase. The company raised its fiscal year 2023 revenue guidance to $362 million, representing a 32% YoY growth. Net revenue in 3Q23 was $93.1 million, with gross margin at 74.2%. Adjusted EBITDA was $14.0 million, and net income was $3.9 million. Cash, cash equivalents, and short-term investments were $344.7 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
earnings
-
News
Axonics to Report Third Quarter 2023 Financial Results on October 30
Rhea-AI Summary
Axonics, Inc. (Nasdaq: AXNX) to report Q3 2023 financial results on October 30. Conference call scheduled at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
conferences earnings
-
News
Axonics to Participate in September Investor Conferences
Rhea-AI Summary
Axonics, Inc. to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
conferences
News
Axonics Announces CFO Retirement and Appoints Successor
Rhea-AI Summary
Axonics, Inc. announces retirement of CFO and appointment of new CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
management
-
News
Axonics Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Axonics, Inc. (AXNX) reports a 35% year-over-year increase in quarterly revenue, reaching $92.9 million. The company's fiscal year 2023 revenue guidance has been raised to $358 million, representing a 31% growth. Axonics attributes its growth to higher utilization and share of wallet at existing customers, onboarding of new accounts, and operational efficiencies. The company's gross margin reached over 75% in the second quarter, resulting in an adjusted EBITDA of over $18 million. Net revenue for 2Q23 was $92.9 million, with a gross margin of 75.6%. Adjusted EBITDA for the same period was $18.4 million. The company made a $35 million milestone payment to Contura Holdings Limited related to Bulkamid achieving over $50 million of sales in the 12-month period ended March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.81%
Tags
earnings
-
News
Axonics to Report Second Quarter 2023 Financial Results on July 27
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
conferences earnings
News
Axonics Reports First Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.04%
Tags
earnings
Stock AXNX logo
Axonics Inc

Nasdaq:AXNX

AXNX Rankings

#1455 Ranked by Market Cap
#3982 Ranked by Stock Gains
N/A Ranked by Dividends

AXNX Stock Data

3.43B
50.43M
1.07%
103.05%
6.74%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Irvine

About AXNX

axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.